INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.4000
-0.2600 (-5.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.6600
Open4.7000
Bid4.35 x 1000
Ask4.49 x 2200
Day's Range4.2941 - 4.7200
52 Week Range3.3500 - 11.6500
Volume724,131
Avg. Volume508,482
Market Cap326.787M
Beta (3Y Monthly)3.10
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.40
Trade prices are not sourced from all markets
  • These Three Cannabis Stocks Are in the Green Today
    Market Realist2 days ago

    These Three Cannabis Stocks Are in the Green Today

    These Three Cannabis Stocks Are in the Green TodayINSYS TherapeuticsToday, INSYS Therapeutics (INSY) is trading at $4.69, up ~8.80% from its close of $4.31 on January 16. On January 16, INSY rose ~2.62% to $4.31 from its previous close of $4.20 on

  • These Cannabis Stocks Are Soaring in January
    Market Realist3 days ago

    These Cannabis Stocks Are Soaring in January

    These Cannabis Stocks Are Soaring in JanuaryCannabis stock trendsCannabis stock CannTrust Holdings (CNTTF) rose to $6.0 on January 15 from $4.8 at the close of market on December 31, 2018, representing a rise of ~25% in the first half of January

  • Here's Why Marijuana Stock Insys Therapeutics Fell More Than 63% in 2018
    Motley Fool4 days ago

    Here's Why Marijuana Stock Insys Therapeutics Fell More Than 63% in 2018

    The opioid business isn't what it used to be.

  • How INSYS Therapeutics’ Earnings Were Trending
    Market Realist5 days ago

    How INSYS Therapeutics’ Earnings Were Trending

    Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively, compared to $180.8 million and $2.50 in the same period the prior year. In the third quarter, INSYS Therapeutics reported net income and diluted EPS of $30.4 million and $0.41, respectively, compared to $166.3 million and $2.28 in the third quarter of 2017. Wall Street analysts anticipate that INSYS Therapeutics is expected to report net income and EPS of $29.21 million and $0.39, respectively, in the fourth quarter of 2018. Analysts also estimate that the company is expected to report net income and EPS of $105.1 million and $1.51, respectively, in fiscal 2018. ## Gross income and profit margin In the first nine months of 2018, INSYS Therapeutics’ (INSY) gross income amounted to $57.4 million compared to $93.1 million in the same period the prior year. In the third quarter, the company’s gross income amounted to $15.97, which is a ~31% YoY decline. Wall Street analysts anticipate INSYS Therapeutics to report gross income of $16.20 million in the fourth quarter of 2018. Analysts also predict that the company’s gross income for fiscal 2018 will be $74.03 million, which represents a ~38.33% YoY decline. In the third quarter, INSYS Therapeutics reported a gross margin of ~87% compared to 75.6% in the third quarter of 2017. ## Recent developments On January 9, INSYS Therapeutics presented results of the dose-evaluation pharmacokinetic study of the company’s epinephrine nasal spray. In the pharmacokinetic study, a dose was identified that is comparable to that of Adrenalin (0.5 mg) and EpiPen (0.3 mg). Adrenalin (0.5 mg) and EpiPen (0.3 mg) both are utilized for the treatment of anaphylaxis. In July 2018, INSYS Therapeutics’ proof-of-concept pharmacokinetic trial epinephrine nasal spray showed rapid drug absorption through the nasal mucosa. The bioavailability of epinephrine nasal spray was demonstrated to be similar to the intramuscular injection of EpiPen (0.3mg). In August 2018, INSYS Therapeutics’ epinephrine nasal spray was granted a fast track designation by the US FDA as investigational therapy for treatment of anaphylaxis. Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 2 - How Is INSYS Therapeutics Financially Positioned in January?

  • How Is INSYS Therapeutics Financially Positioned in January?
    Market Realist7 days ago

    How Is INSYS Therapeutics Financially Positioned in January?

    Cannabis Stock INSYS Therapeutics Is on the Rise in January (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million. In the third quarter, the company’s revenues declined ~40% YoY to reach $18.3 million from $30.7 million. Wall Street analysts estimate that INSYS Therapeutics is expected to generate revenues of $17.95 million in the fourth quarter of fiscal 2018, which represents a ~42.99% YoY decline. Analysts also estimate that INSYS Therapeutics will report net revenues of $83.74 million for fiscal 2018, which represents a ~40.48% YoY decline. Analysts estimate that GW Pharmaceuticals (GWPH) and Cara Therapeutics (CARA), INSYS Therapeutics’ peers in the cannabinoid drugs market, will report net revenues of $8.7 million and $10.9 million, respectively. GW Pharmaceuticals is expected to deliver ~13.52% YoY revenue growth in fiscal 2018. INSYS Therapeutics and Lunatus signed a licensing agreement for the commercialization of Subsys in the Middle East market. The agreement could boost INSYS Therapeutics’ global footprint and business growth. ## Expenditure trends In the first nine months of 2018, INSYS Therapeutics’ cost of revenue amounted to $8.2 million compared to $16.0 million in the same period the prior year. Wall Street analysts anticipate INSYS Therapeutics’ cost of revenue to be around $9.7 million in fiscal 2018. In the first nine months of 2018, INSYS Therapeutics’ net expenses in sales and marketing (or S&M) amounted to $25.5 million compared to $41.7 million in the same period the prior year. INSYS Therapeutics reported R&D (research & development) and G&A (general & administrative) expenses of $43.2 million and $29.3 million, respectively, compared to $46.6 million and $31.8 million in the same period the prior year. Wall Street analysts estimate that the company’s S&M, G&A, and R&D expenditure will be around $32.49 million, $89.50 million, and $58.78 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Cannabis Stock INSYS Therapeutics Has Risen 28% in January * Part 3 - How INSYS Therapeutics’ Earnings Were Trending

  • Cannabis Stock INSYS Therapeutics Has Risen 28% in January
    Market Realist7 days ago

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of market on December 31. On January 2, 2019, INSYS Therapeutics stock price grew ~24.29% to reach $4.35 from its prior day close of $3.50 on December 31, 2018.

  • A Look into GW Pharmaceuticals’ Revenue Trends
    Market Realist8 days ago

    A Look into GW Pharmaceuticals’ Revenue Trends

    Cannabis Stock GW Pharmaceuticals Growing Steadily in January (Continued from Prior Part) ## Revenue trends In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year, reflecting ~1% YoY growth. In fiscal 2018, GW Pharmaceuticals’ net revenues grew ~15.75% YoY to reach $12.74 from $11.00. In the fourth quarter of 2018, GW Pharmaceuticals generated revenues of $10.5 million from product sales compared to $8.0 million in the same period the prior year, reflecting ~32% YoY growth. Wall Street analysts estimate that GW Pharmaceuticals will generate revenues of $8.8 million in the first quarter of fiscal 2019, which represents ~15.75% YoY growth. Analysts also estimate that GW Pharmaceuticals’ net revenues in fiscal 2019 will be around $122.66 million. GW Pharmaceuticals is strengthening its supply chain of Epidiolex. GW Pharmaceuticals’ regulatory filing for approval of Epidiolex in the European market is under review by the European Medicines Agency (or EMA). The company anticipates the EMA’s decision by the first quarter of fiscal 2019. The approval of the drug in the European market could significantly boost the revenue growth of GW Pharmaceuticals. ## Peers’ performance Cara Therapeutics (CARA) and Insys Therapeutics (INSY), GW Pharmaceuticals’ peers in the medical cannabis market, reported revenues of $5.0 million and $18.35 million, respectively, in the third quarter of fiscal 2018. Wall Street analysts estimate that Cara Therapeutics and Insys Therapeutics will report net revenues of $10.9 million and $83.74 million, respectively, in fiscal 2018. The revenue growth of GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics could boost the ETFMG Alternative Harvest ETF (MJ). GW Pharmaceuticals, Cara Therapeutics, and Insys Therapeutics make up ~5.95%, ~1.52%, and ~1.64% of MJ’s total portfolio holding. In the next article, we’ll discuss GW Pharmaceuticals’ other earnings and operational expenditure trends. Continue to Next Part Browse this series on Market Realist: * Part 1 - GW Pharmaceuticals Has Already Soared 23% in January * Part 3 - How GW Pharmaceuticals’ Earnings Are Trending * Part 4 - Here Are Some of GW Pharmaceuticals’ Key Growth Drivers

  • INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
    Zacks9 days ago

    INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

    INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.

  • Former Insys CEO pleads guilty to opioid kickback scheme
    Reuters9 days ago

    Former Insys CEO pleads guilty to opioid kickback scheme

    The former chief executive of Insys Therapeutics Inc (INSY.O) pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker's CEO in 2015, pleaded guilty in federal court in Boston to conspiracy and mail fraud charges after entering into a cooperation deal with prosecutors. Babich, 42, faces up to 25 years in prison.

  • GlobeNewswire10 days ago

    INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray.

  • The 10 Worst-Performing Marijuana Stocks in 2018
    Motley Fool11 days ago

    The 10 Worst-Performing Marijuana Stocks in 2018

    These pot stocks all lost at least half of their value.

  • Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?
    Investor's Business Daily14 days ago

    Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine?

    Now that one cannabis-based drug has won FDA approval, a wide range of drugmakers, from small biotech stocks to giant pharma firms, are exploring the substance to treat a host of maladies.

  • GlobeNewswire16 days ago

    INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

    PHOENIX, Jan. 03, 2019 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray.

  • ACCESSWIRE19 days ago

    Cannabis Firms Set to Explode

    HENDERSON, NV / ACCESSWIRE / December 31, 2018 / The market is rallying, and cannabis stocks are ready to rally as well. The companies below could lead the charge heading into 2019. An extremely interesting ...

  • Ex-Insys CEO to plead guilty to opioid kickback scheme
    Reuters23 days ago

    Ex-Insys CEO to plead guilty to opioid kickback scheme

    The former chief executive of Insys Therapeutics Inc (INSY.O) has agreed to plead guilty to participating in a scheme to bribe doctors to prescribe a powerful opioid medication in order to boost its sales, U.S. prosecutors said on Wednesday. Michael Babich, who resigned as the Arizona-based drugmaker's CEO in 2015 and was due to face trial next month, has agreed to plead guilty to conspiracy and mail fraud charges, federal prosecutors in Boston disclosed in a court filing. Five former Insys executives and managers indicted along with Babich, including John Kapoor, the company's founder and former chairman, remain scheduled to go on trial in late January.

  • 2 Marijuana Stocks That Could Be Halved in 2019
    Motley Fool26 days ago

    2 Marijuana Stocks That Could Be Halved in 2019

    These pot stocks could be a real buzzkill in the new year.

  • What’s Auxly Cannabis’ MidStream Strategy in 2018?
    Market Realist29 days ago

    What’s Auxly Cannabis’ MidStream Strategy in 2018?

    Auxly Cannabis (CBWTF) competes with multiple players like Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Insys Therapeutics (INSY), Aphria (APHA), Aurora Cannabis (ACB), and Canopy Growth (CGC) in areas like pharmaceutical, health and wellness, vertical integration, and adult use in the midstream segment.

  • More Than 1.9 Million Californians May Own Pot Stocks Without Realizing It
    Motley Fool29 days ago

    More Than 1.9 Million Californians May Own Pot Stocks Without Realizing It

    This $350 billion pension fund has been actively adding marijuana stocks.

  • Benzingalast month

    Analyst: Insys To Benefit As FDA Pushes Naloxone Access

    As Insys Therapeutics Inc (NASDAQ: INSY ) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage ...

  • Reuterslast month

    New Hampshire physician assistant guilty of Insys opioid kickback scheme

    A federal jury in Concord, New Hampshire, found Christopher Clough, 45, guilty of all charges he faced in a case that stemmed from a years-long investigation into the Arizona company's efforts to promote its opioid medication Subsys. Patrick Richard, Clough's lawyer, said he is evaluating his options, including an appeal. The verdict came a month before six former Insys executives and managers including John Kapoor, a onetime billionaire who was its founder and chairman, face trial on charges that they conspired to bribe medical practitioners to prescribe Subsys.

  • Reuterslast month

    New Hampshire physician assistant guilty of Insys opioid kickback scheme

    A former physician assistant in New Hampshire was convicted on Tuesday of charges that he accepted nearly $50,000 in kickbacks from Insys Therapeutics Inc in exchange for prescribing its addictive fentanyl spray. A federal jury in Concord, New Hampshire, found Christopher Clough, 45, guilty of all charges he faced in a case that stemmed from a years-long investigation into the Arizona company's efforts to promote its opioid medication Subsys. Patrick Richard, Clough's lawyer, said he is evaluating his options, including an appeal.

  • Market Exclusivelast month

    INSYS announces Progress on Spray Technology Products, CBD Pharmaceuticals

    INSYS Therapeutics, Inc. (NASDAQ:INSY) has today given information on the progress of their product pipeline that includes CBD oral solution and naloxone and epinephrine nasal sprays. According to the company president and CEO, Saeed Motahari, the strategic change of moving away from opioids to the production of new drug delivery systems and CBD pharmaceuticals is […] The post INSYS announces Progress on Spray Technology Products, CBD Pharmaceuticals appeared first on Market Exclusive.

  • GlobeNewswirelast month

    INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018.

  • GlobeNewswirelast month

    INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today provided an update on its product pipeline, which includes cannabidiol (CBD) oral solution as well as epinephrine and naloxone nasal sprays. “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

  • Surprise! The Largest U.S. Pension Fund Just Bought These 2 Marijuana Stocks
    Motley Foollast month

    Surprise! The Largest U.S. Pension Fund Just Bought These 2 Marijuana Stocks

    And you might scratch your head over the pension fund's picks.